{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T01:04:00Z","timestamp":1787965440148,"version":"build-2784847793"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:00:00Z","timestamp":1706400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medical Genetics"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ejmg.2024.104915","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T20:22:58Z","timestamp":1707164578000},"page":"104915","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Impressive clinical improvement and disappearance of neuropathic pain in an adult patient with hypophosphatasia treated with asfotase alfa"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5277-6202","authenticated-orcid":false,"given":"Zografia","family":"Zervou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roel","family":"Plooij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evert F.S.","family":"van Velsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remco G.M.","family":"Timmermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serwet","family":"Demirdas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Carola","family":"Zillikens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.ejmg.2024.104915_bib1","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s00198-015-3272-1","article-title":"Hypophosphatasia: an overview of the disease and its treatment","volume":"26","author":"Bianchi","year":"2015","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.ejmg.2024.104915_bib2","series-title":"Vitamin B6 Deficiency","author":"Brown","year":"2023"},{"issue":"3","key":"10.1016\/j.ejmg.2024.104915_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/10408369109106862","article-title":"Hypophosphatasia and the extracellular metabolism of inorganic pyrophosphate: clinical and laboratory aspects","volume":"28","author":"Caswell","year":"1991","journal-title":"Crit. Rev. Clin. Lab Sci."},{"key":"10.1016\/j.ejmg.2024.104915_bib4","series-title":"The Brief Pain Inventory User Guide","first-page":"1","author":"Cleeland","year":"2009"},{"issue":"2","key":"10.1016\/j.ejmg.2024.104915_bib5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00198-018-4691-6","article-title":"Neurological symptoms in hypophosphatasia","volume":"30","author":"Colazo","year":"2019","journal-title":"Osteoporos. Int."},{"issue":"6","key":"10.1016\/j.ejmg.2024.104915_bib6","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/jnc.13950","article-title":"Identification of altered brain metabolites associated with TNAP activity in a mouse model of hypophosphatasia using untargeted NMR-based metabolomics analysis","volume":"140","author":"Cruz","year":"2017","journal-title":"J. Neurochem."},{"issue":"11","key":"10.1016\/j.ejmg.2024.104915_bib7","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med. Care"},{"issue":"48","key":"10.1016\/j.ejmg.2024.104915_bib8","article-title":"Improvement of bone microarchitecture parameters after 12 months of treatment with asfotase alfa in adult patient with hypophosphatasia: case report","volume":"97","author":"Freitas","year":"2018","journal-title":"Medicine (Baltim.)"},{"issue":"9","key":"10.1016\/j.ejmg.2024.104915_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10395","article-title":"Physical function and health-related quality of life in adults treated with asfotase alfa for pediatric-onset hypophosphatasia","volume":"4","author":"Genest","year":"2020","journal-title":"JBMR Plus"},{"key":"10.1016\/j.ejmg.2024.104915_bib10","series-title":"Het meten van problemen met zelfredzaamheid op verzorgend en huishoudelijk gebied met de Groninger Activiteiten Restrictie Schaal","author":"Gijm","year":"2012"},{"issue":"3","key":"10.1016\/j.ejmg.2024.104915_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/hec.4730020305","article-title":"The RAND 36-item health survey 1.0","volume":"2","author":"Hays","year":"1993","journal-title":"Health Econ."},{"issue":"2","key":"10.1016\/j.ejmg.2024.104915_bib12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s12018-013-9139-0","article-title":"Clinical aspects of hypophosphatasia: an update","volume":"11","author":"Hofmann","year":"2013","journal-title":"Clin. Rev. Bone Miner. Metabol."},{"issue":"4","key":"10.1016\/j.ejmg.2024.104915_bib13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/geront\/30.4.497","article-title":"The development of a hierarchical polychotomous ADL-IADL scale for noninstitutionalized elders","volume":"30","author":"Kempen","year":"1990","journal-title":"Gerontol."},{"key":"10.1016\/j.ejmg.2024.104915_bib14","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bone.2018.12.011","article-title":"Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia","volume":"121","author":"Kishnani","year":"2019","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.ejmg.2024.104915_bib15","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/jbm4.10052","article-title":"Fracture healing in two adult patients with hypophosphatasia after asfotase alfa therapy","volume":"2","author":"Klidaras","year":"2018","journal-title":"JBMR Plus"},{"issue":"6","key":"10.1016\/j.ejmg.2024.104915_bib16","first-page":"e344","article-title":"Adult-onset hypophosphatasia: before and after treatment with asfotase alfa","volume":"5","author":"Magdaleno","year":"2019","journal-title":"AACE Clin. Case Rep."},{"key":"10.1016\/j.ejmg.2024.104915_bib17","article-title":"Marked motor function improvement in a 32-year-old woman with childhood-onset hypophosphatasia by asfotase alfa therapy: evaluation based on standardized testing batteries used in Duchenne muscular dystrophy clinical trials","volume":"25","author":"Nishizawa","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"5","key":"10.1016\/j.ejmg.2024.104915_bib18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-SD: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann. Med."},{"key":"10.1016\/j.ejmg.2024.104915_bib19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.bone.2019.05.036","article-title":"Recovery of bone mineralization and quality during asfotase alfa treatment in an adult patient with infantile-onset hypophosphatasia","volume":"127","author":"Rolvien","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.ejmg.2024.104915_bib20","first-page":"1","article-title":"Het meten van de algemene gezondheidstoestand met de RAND-36","volume":"3","author":"van der Zee","year":"1993","journal-title":"Noordelijk Centrum voor Gezondheidsvraagstukken, reeks meetinstrumenten"},{"issue":"4","key":"10.1016\/j.ejmg.2024.104915_bib21","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","article-title":"Dutch tariff for the five-level version of EQ-5D","volume":"19","author":"Versteegh","year":"2016","journal-title":"Value Health"},{"issue":"3","key":"10.1016\/j.ejmg.2024.104915_bib22","first-page":"289","article-title":"Active search of adult patients with persistently low serum alkaline phosphatase levels for the diagnosis of hypophosphatasia","volume":"65","author":"Vieira","year":"2021","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.ejmg.2024.104915_bib23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.tiv.2017.07.009","article-title":"The vitamin B6 paradox: supplementation with high concentrations of pyridoxine leads to decreased vitamin B6 function","volume":"44","author":"Vrolijk","year":"2017","journal-title":"Toxicol. Vitro"},{"issue":"6","key":"10.1016\/j.ejmg.2024.104915_bib24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med. Care"},{"issue":"4","key":"10.1016\/j.ejmg.2024.104915_bib25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nrendo.2016.14","article-title":"Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment","volume":"12","author":"Whyte","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.ejmg.2024.104915_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bone.2017.02.011","article-title":"Hypophosphatasia: an overview for 2017","volume":"102","author":"Whyte","year":"2017","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.ejmg.2024.104915_bib27","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/jbmr.3075","article-title":"Hypophosphatasia: enzyme replacement therapy brings new opportunities and new challenges","volume":"32","author":"Whyte","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ejmg.2024.104915_bib28","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.bone.2015.02.022","article-title":"Hypophosphatasia: validation and expansion of the clinical nosology for children from 25 years experience with 173 pediatric patients","volume":"75","author":"Whyte","year":"2015","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.ejmg.2024.104915_bib29","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1210\/jc.2015-3462","article-title":"Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia","volume":"101","author":"Whyte","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.ejmg.2024.104915_bib30","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85971","article-title":"Asfotase alfa therapy for children with hypophosphatasia","volume":"1","author":"Whyte","year":"2016","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.ejmg.2024.104915_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S2213-8587(18)30307-3","article-title":"Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol."}],"container-title":["European Journal of Medical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769721224000077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1769721224000077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:55:36Z","timestamp":1761710136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1769721224000077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":31,"alternative-id":["S1769721224000077"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmg.2024.104915","relation":{},"ISSN":["1769-7212"],"issn-type":[{"value":"1769-7212","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impressive clinical improvement and disappearance of neuropathic pain in an adult patient with hypophosphatasia treated with asfotase alfa","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medical Genetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmg.2024.104915","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104915"}}